Replies to post #154212 on Biotech Values

[biomaven0]

>>TEVA

lowest P/E ratio

I find it hard to think about the earnings for these generic companies. They keep getting these 6-month-exclusivity sugar rushes and it's hard to know exactly where the next ones are coming from. I'm sure the analysts that follow these companies have detailed models, but it's tough for outsiders to get a good intuitive sense.

I owned Teva for a few years after they bought IVAX but fortunately exited a while back.

Peter

[genisi]

Factoid: Teva has the lowest P/E ratio* of any consistently profitable drug/biotech company.

Corollary: Most investors don’t think thrice-weekly Copaxone is likely to be an effective lifecycle-management fix for the Copaxone franchise, as Teva contends.

Investors don't think Teva's strategy as a whole is convincing: its intention to focus on New Therapeutic Entity (NTE), no mention of exciting program in the pipeline, etc.